Antibiotic Use in Sub-Saharan Africa: Challenges and Strategies
By Crystal Lubbe
October 29, 2024
The article titled “Antibiotic prescription sources and use among under-5 children with fever/cough in sub-Saharan Africa” provides a critical analysis of antibiotic use and prescription sources for children under 5 with fever or cough in sub-Saharan Africa (SSA). In particular, this analysis sheds light on the significant issue of antibiotic misuse, thereby emphasising the necessity for appropriate interventions.
Methodology
The study used data from the Demographic and Health Surveys (DHS) from 2006 to 2021, covering 37 SSA countries and including 18,866 children under 5 with fever or cough.
Main Findings
Overall, the majority of children received antibiotics from unqualified sources, which highlights a significant issue with inappropriate use in the region. Moreover, the study identified that children with formally educated mothers were more likely to receive antibiotics from qualified sources. This finding stressed the vital role of maternal education in improving antibiotic prescription sources.
Implications and Recommendations
Consequently, these findings stress the need to address healthcare disparities, enhance access to qualified providers, and promote maternal education, to ensure proper antibiotic use. Moreover, there is an urgency for targeted interventions and policies to optimise antibiotic prescribing practices and combat AMR in sub-Saharan Africa.
Antimicrobial Resistance
The World Health Organization’s 2022 report highlights AMR as a leading cause of death, attributing 5 million deaths in 2019 to bacterial AMR. The United Nations warns that AMR can lead to 10 million deaths annually by 2050, resulting in severe economic consequences.
Gap in Existing Literature
The study addresses a gap by focusing on children under 5 with fever or cough in SSA. This population has often been overlooked in research, which typically focused on adults or limited simulations in a few countries.
Conclusion
The study offers insights into antibiotic prescription patterns and determinants for children under 5 in sub-Saharan Africa. This stresses the need for effective interventions to ensure proper antibiotic use and reduce antimicrobial resistance risks. Addressing these issues is vital for the health of children in the region.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
